PortalPublikationenGrowth differentiation factor 15 plasma levels and outcome a...

Growth differentiation factor 15 plasma levels and outcome after ischemic stroke

Standard

Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. / Worthmann, Hans; Kempf, Tibor; Widera, Christian; Tryc, Anita B; Goldbecker, Annemarie; Ma, Yue T; Deb-Chatterji, Milani; Tountopoulou, Argyro; Lambrecht, Jürgen; Heeren, Meike; Lichtinghagen, Ralf; Wollert, Kai C; Weissenborn, Karin.

in: CEREBROVASC DIS, Jahrgang 32, Nr. 1, 2011, S. 72-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Worthmann, H, Kempf, T, Widera, C, Tryc, AB, Goldbecker, A, Ma, YT, Deb-Chatterji, M, Tountopoulou, A, Lambrecht, J, Heeren, M, Lichtinghagen, R, Wollert, KC & Weissenborn, K 2011, 'Growth differentiation factor 15 plasma levels and outcome after ischemic stroke', CEREBROVASC DIS, Jg. 32, Nr. 1, S. 72-8. https://doi.org/10.1159/000328233

APA

Worthmann, H., Kempf, T., Widera, C., Tryc, A. B., Goldbecker, A., Ma, Y. T., Deb-Chatterji, M., Tountopoulou, A., Lambrecht, J., Heeren, M., Lichtinghagen, R., Wollert, K. C., & Weissenborn, K. (2011). Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. CEREBROVASC DIS, 32(1), 72-8. https://doi.org/10.1159/000328233

Vancouver

Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, Ma YT et al. Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. CEREBROVASC DIS. 2011;32(1):72-8. https://doi.org/10.1159/000328233

Bibtex

@article{793659db04464413808475f3dff9aa23,
title = "Growth differentiation factor 15 plasma levels and outcome after ischemic stroke",
abstract = "BACKGROUND: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that is induced after experimental brain injury. We hypothesized that the circulating levels of GDF-15 are increased and associated with neurological outcome in patients with ischemic stroke.METHODS: Serial blood samples were obtained between 6 h and 7 days after symptom onset in 57 consecutive patients with acute ischemic stroke (n = 51) or transient ischemic attack (n = 6). GDF-15 was measured by immunoradiometric assay. Neurological outcome using the modified Rankin Scale (mRS) at 7 and 90 days was classified as favorable (mRS 0 or 1) or unfavorable (mRS >1).RESULTS: Six hours after symptom onset, GDF-15 levels were abnormally high (>1,200 ng/l) in 68% of the patients. They declined by 8% over the course of 7 days (p < 0.001). GDF-15 levels were correlated with the circulating levels of the inflammatory marker interleukin-6 and the glial protein S100 calcium binding protein B, and with carotid intima-media thickness. Ischemic stroke patients with an mRS score >1 at 7 or 90 days had higher circulating levels of GDF-15 at all preceding sampling time points compared to patients with an mRS score of 0 or 1 (p ≤ 0.002). Similarly, in a logistic regression analysis, GDF-15 levels measured between 6 h and 7 days after symptom onset were associated with mRS at 7 and 90 days.CONCLUSIONS: These data show for the first time that the circulating levels of GDF-15 are elevated and associated with neurological outcome in patients with ischemic stroke.",
keywords = "Aged, Aged, 80 and over, Biomarkers, Female, Growth Differentiation Factor 15, Humans, Ischemic Attack, Transient, Male, Nerve Growth Factors, Neurologic Examination, Predictive Value of Tests, Prognosis, Regression Analysis, Retrospective Studies, S100 Calcium Binding Protein beta Subunit, S100 Proteins, Sensitivity and Specificity, Stroke, Time Factors, Journal Article, Research Support, Non-U.S. Gov't",
author = "Hans Worthmann and Tibor Kempf and Christian Widera and Tryc, {Anita B} and Annemarie Goldbecker and Ma, {Yue T} and Milani Deb-Chatterji and Argyro Tountopoulou and J{\"u}rgen Lambrecht and Meike Heeren and Ralf Lichtinghagen and Wollert, {Kai C} and Karin Weissenborn",
note = "Copyright {\textcopyright} 2011 S. Karger AG, Basel.",
year = "2011",
doi = "10.1159/000328233",
language = "English",
volume = "32",
pages = "72--8",
journal = "CEREBROVASC DIS",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "1",

}

RIS

TY - JOUR

T1 - Growth differentiation factor 15 plasma levels and outcome after ischemic stroke

AU - Worthmann, Hans

AU - Kempf, Tibor

AU - Widera, Christian

AU - Tryc, Anita B

AU - Goldbecker, Annemarie

AU - Ma, Yue T

AU - Deb-Chatterji, Milani

AU - Tountopoulou, Argyro

AU - Lambrecht, Jürgen

AU - Heeren, Meike

AU - Lichtinghagen, Ralf

AU - Wollert, Kai C

AU - Weissenborn, Karin

N1 - Copyright © 2011 S. Karger AG, Basel.

PY - 2011

Y1 - 2011

N2 - BACKGROUND: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that is induced after experimental brain injury. We hypothesized that the circulating levels of GDF-15 are increased and associated with neurological outcome in patients with ischemic stroke.METHODS: Serial blood samples were obtained between 6 h and 7 days after symptom onset in 57 consecutive patients with acute ischemic stroke (n = 51) or transient ischemic attack (n = 6). GDF-15 was measured by immunoradiometric assay. Neurological outcome using the modified Rankin Scale (mRS) at 7 and 90 days was classified as favorable (mRS 0 or 1) or unfavorable (mRS >1).RESULTS: Six hours after symptom onset, GDF-15 levels were abnormally high (>1,200 ng/l) in 68% of the patients. They declined by 8% over the course of 7 days (p < 0.001). GDF-15 levels were correlated with the circulating levels of the inflammatory marker interleukin-6 and the glial protein S100 calcium binding protein B, and with carotid intima-media thickness. Ischemic stroke patients with an mRS score >1 at 7 or 90 days had higher circulating levels of GDF-15 at all preceding sampling time points compared to patients with an mRS score of 0 or 1 (p ≤ 0.002). Similarly, in a logistic regression analysis, GDF-15 levels measured between 6 h and 7 days after symptom onset were associated with mRS at 7 and 90 days.CONCLUSIONS: These data show for the first time that the circulating levels of GDF-15 are elevated and associated with neurological outcome in patients with ischemic stroke.

AB - BACKGROUND: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that is induced after experimental brain injury. We hypothesized that the circulating levels of GDF-15 are increased and associated with neurological outcome in patients with ischemic stroke.METHODS: Serial blood samples were obtained between 6 h and 7 days after symptom onset in 57 consecutive patients with acute ischemic stroke (n = 51) or transient ischemic attack (n = 6). GDF-15 was measured by immunoradiometric assay. Neurological outcome using the modified Rankin Scale (mRS) at 7 and 90 days was classified as favorable (mRS 0 or 1) or unfavorable (mRS >1).RESULTS: Six hours after symptom onset, GDF-15 levels were abnormally high (>1,200 ng/l) in 68% of the patients. They declined by 8% over the course of 7 days (p < 0.001). GDF-15 levels were correlated with the circulating levels of the inflammatory marker interleukin-6 and the glial protein S100 calcium binding protein B, and with carotid intima-media thickness. Ischemic stroke patients with an mRS score >1 at 7 or 90 days had higher circulating levels of GDF-15 at all preceding sampling time points compared to patients with an mRS score of 0 or 1 (p ≤ 0.002). Similarly, in a logistic regression analysis, GDF-15 levels measured between 6 h and 7 days after symptom onset were associated with mRS at 7 and 90 days.CONCLUSIONS: These data show for the first time that the circulating levels of GDF-15 are elevated and associated with neurological outcome in patients with ischemic stroke.

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers

KW - Female

KW - Growth Differentiation Factor 15

KW - Humans

KW - Ischemic Attack, Transient

KW - Male

KW - Nerve Growth Factors

KW - Neurologic Examination

KW - Predictive Value of Tests

KW - Prognosis

KW - Regression Analysis

KW - Retrospective Studies

KW - S100 Calcium Binding Protein beta Subunit

KW - S100 Proteins

KW - Sensitivity and Specificity

KW - Stroke

KW - Time Factors

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1159/000328233

DO - 10.1159/000328233

M3 - SCORING: Journal article

C2 - 21613788

VL - 32

SP - 72

EP - 78

JO - CEREBROVASC DIS

JF - CEREBROVASC DIS

SN - 1015-9770

IS - 1

ER -